499 related articles for article (PubMed ID: 30463359)
1. Aberrant RNA Splicing in Cancer and Drug Resistance.
Wang BD; Lee NH
Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30463359
[TBL] [Abstract][Full Text] [Related]
2. Targeting Splicing in Prostate Cancer.
Antonopoulou E; Ladomery M
Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29693622
[TBL] [Abstract][Full Text] [Related]
3. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
[TBL] [Abstract][Full Text] [Related]
4. Aberrant PI3Kδ splice isoform as a potential biomarker and novel therapeutic target for endocrine cancers.
Ha S; Gujrati H; Wang BD
Front Endocrinol (Lausanne); 2023; 14():1190479. PubMed ID: 37670888
[TBL] [Abstract][Full Text] [Related]
5. The RNA helicase DDX39B and its paralog DDX39A regulate androgen receptor splice variant AR-V7 generation.
Nakata D; Nakao S; Nakayama K; Araki S; Nakayama Y; Aparicio S; Hara T; Nakanishi A
Biochem Biophys Res Commun; 2017 Jan; 483(1):271-276. PubMed ID: 28025139
[TBL] [Abstract][Full Text] [Related]
6. Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.
Jyotsana N; Heuser M
Expert Opin Ther Targets; 2018 Feb; 22(2):107-121. PubMed ID: 29235382
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer: Alternatively spliced mRNA transcripts in tumor progression and their uses as therapeutic targets.
Calderon-Aparicio A; Wang BD
Int J Biochem Cell Biol; 2021 Dec; 141():106096. PubMed ID: 34653618
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of splice-switching oligonucleotides.
Bauman J; Jearawiriyapaisarn N; Kole R
Oligonucleotides; 2009 Mar; 19(1):1-13. PubMed ID: 19125639
[TBL] [Abstract][Full Text] [Related]
9. RNA splicing: a dual-edged sword for hepatocellular carcinoma.
Kashyap A; Tripathi G; Tripathi A; Rao R; Kashyap M; Bhat A; Kumar D; Rajhans A; Kumar P; Chandrashekar DS; Mahmood R; Husain A; Zayed H; Bharti AC; Kashyap MK
Med Oncol; 2022 Aug; 39(11):173. PubMed ID: 35972700
[TBL] [Abstract][Full Text] [Related]
10. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy.
Mehterov N; Kazakova M; Sbirkov Y; Vladimirov B; Belev N; Yaneva G; Todorova K; Hayrabedyan S; Sarafian V
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356101
[TBL] [Abstract][Full Text] [Related]
11. Antisense Oligonucleotide-Mediated Splice Switching: Potential Therapeutic Approach for Cancer Mitigation.
Raguraman P; Balachandran AA; Chen S; Diermeier SD; Veedu RN
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771719
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Tak1 alternative splicing by splice-switching oligonucleotides.
Zhou D; Shao Q; Fan X; Wu P; Lin W; Wei H; He F; Jiang Y
Biochem Biophys Res Commun; 2018 Mar; 497(4):1018-1024. PubMed ID: 29475001
[TBL] [Abstract][Full Text] [Related]
13. Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing.
Shkreta L; Bell B; Revil T; Venables JP; Prinos P; Elela SA; Chabot B
Cancer Treat Res; 2013; 158():41-94. PubMed ID: 24222354
[TBL] [Abstract][Full Text] [Related]
14. The role of KLF6 and its splice variants in cancer therapy.
DiFeo A; Martignetti JA; Narla G
Drug Resist Updat; 2009; 12(1-2):1-7. PubMed ID: 19097929
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the regulatory effects of synthesized antisense oligonucleotides on androgen receptor (AR) exon 3 splicing in prostate cancer cells.
Wang L; Gong S; Zhang X; Azhar Z; Chen J
Gene; 2023 May; 866():147330. PubMed ID: 36871670
[TBL] [Abstract][Full Text] [Related]
16. Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids.
Wan L; Kral AJ; Voss D; Schäfer B; Sudheendran K; Danielsen M; Caruthers MH; Krainer AR
Nucleic Acid Ther; 2024 May; ():. PubMed ID: 38716830
[TBL] [Abstract][Full Text] [Related]
17. Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities.
Venkataramany AS; Schieffer KM; Lee K; Cottrell CE; Wang PY; Mardis ER; Cripe TP; Chandler DS
Ann Oncol; 2022 Jun; 33(6):578-592. PubMed ID: 35339647
[TBL] [Abstract][Full Text] [Related]
18. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.
Urbanski LM; Leclair N; Anczuków O
Wiley Interdiscip Rev RNA; 2018 Jul; 9(4):e1476. PubMed ID: 29693319
[TBL] [Abstract][Full Text] [Related]
19. Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.
Inoue K; Fry EA
Int J Cancer; 2016 Jul; 139(1):33-41. PubMed ID: 26802432
[TBL] [Abstract][Full Text] [Related]
20. Overcoming imatinib resistance conferred by the
Liu J; Bhadra M; Sinnakannu JR; Yue WL; Tan CW; Rigo F; Ong ST; Roca X
Oncotarget; 2017 Sep; 8(44):77567-77585. PubMed ID: 29100409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
